Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-10-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the fifth board of directors' third meeting of Tianyu Bio-Technology Co., Ltd. It includes details about the meeting date, attendance, and voting results on two proposals: approval of the 2025 Q3 report and continuation of commodity futures hedging business. The document explicitly states that the detailed 2025 Q3 report is published separately on the Shanghai Stock Exchange website, indicating this document is not the report itself but an announcement of board meeting decisions. The content focuses on board meeting resolutions rather than full financial statements or detailed financial analysis. Therefore, this document fits best under Board/Management Information (MANG) as it announces board meeting resolutions and related management decisions.
2025-10-29 Chinese
关于公司2025年度对外担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianyu Bio-Tech Co., Ltd. regarding the progress of its external guarantees for the fiscal year 2025. It details the guarantee amounts, the parties involved, internal decision procedures, and financial data of the guaranteed entity. The document is relatively short (3197 characters) and focuses on the status and details of guarantees rather than presenting comprehensive financial statements or audit results. It is not a full annual or interim report, nor is it an earnings release or management discussion. The content aligns with a regulatory announcement about financing-related guarantees and risk disclosures. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing-related guarantee activities and risk exposure.
2025-10-28 Chinese
关于变更保荐机构及保荐代表人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the company's sponsor institution and sponsor representatives for a securities issuance. It details the transition from one sponsor (Zhongde Securities) to another (Guohai Securities) for the ongoing supervision of the company's fundraising activities. The document includes meeting dates, regulatory approvals, and resumes of the new sponsor representatives. It does not contain financial statements, audit opinions, or detailed financial results. It is a regulatory announcement about management and procedural changes related to capital raising activities, specifically about the sponsor institution change. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on the company's fundraising and capital structure supervision.
2025-10-24 Chinese
第五届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's fifth board of directors' second meeting. It details the meeting's convening, attendance, and voting results on various proposals related to the company's 2025 targeted issuance of A shares, governance structure updates, and shareholder return plans. The text does not contain financial statements or detailed financial analysis but rather reports on board decisions and approvals. It is not a full annual or interim report, nor an earnings release or audit report. The document is an official announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is about 2500 characters, consistent with a meeting resolution announcement rather than a full report.
2025-10-22 Chinese
未来三年股东回报规划（2025年-2027年）（修订稿）
Regulatory Filings Classification · 85% confidence The document is titled as a "Future Three-Year Shareholder Return Plan (2025-2027)" and details the company's profit distribution policy, dividend distribution methods, decision-making procedures, and principles for shareholder returns over the next three years. It is a policy or planning document related to dividends and shareholder returns rather than an announcement of dividend amounts or payment dates. It does not contain actual financial statements or results, nor is it a report or announcement of voting results. The document is a detailed plan regarding dividends and shareholder returns, which fits best under the category of Notice of Dividend Amount (DIV) as it relates to dividend policy and shareholder returns planning. However, since it is a planning document rather than a specific dividend amount announcement, it is more appropriate to classify it as a Regulatory Filing (RNS) because it does not fit neatly into other categories and is a regulatory disclosure about dividend policy and shareholder returns planning. The document length is 2684 characters, which is relatively short but contains substantive policy content, not just a brief announcement or a report publication notice. Therefore, the best classification is Regulatory Filings (RNS).
2025-10-22 Chinese
2025年度向特定对象发行A股股票募集资金使用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度向特定对象发行A股股票募集资金使用可行性分析报告（修订稿）" which translates to "2025 Feasibility Analysis Report on the Use of Funds Raised from a Private Placement of A Shares." It discusses the company's plan to issue shares to specific investors, the use of the raised funds, financial ratios, and the impact on the company's financial condition. The content focuses on capital raising and the use of proceeds from the issuance of shares. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is a detailed feasibility analysis related to a capital raising event. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3449 characters, which is sufficient for a detailed report rather than a brief announcement. Hence, it is not a Report Publication Announcement (RPA).
2025-10-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.